Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully raised a total of RMB 150 million (USD 21.73 million) across its Series A+, B, and B+ financing rounds. The funding rounds were led by ESCO Lifesciences Group, Luxin Venture Capital, and Qiming Venture Partners, respectively, with additional contributions from Qianhai Infrastructure Investment Fund, Jintou Zhiyuan (Jiangsu) Equity Investment Fund, Addor Capital, and Matrix Partners.
Funding and Future Plans
The proceeds from these financing rounds will be directed towards the research and development (R&D) of upstream Chemistry, Manufacturing, and Controls (CMC) process and tool products. Inscinstech plans to use the funds to enhance its manufacturing capacity and expand its global market presence. This strategic allocation of resources underscores the company’s commitment to innovation and growth in the biotechnology sector.
Company Background and Product Portfolio
Inscinstech operates R&D centers in Suzhou and Beijing, China, as well as in Boston, Massachusetts, in the United States. The company is known for its advanced product portfolio, which includes a protein purification system, large – scale nucleic acid synthesis instrument, nano drug assembly system, and other innovative biotech tools. These products are designed to improve the efficiency and effectiveness of biological separation processes, positioning Inscinstech as a key player in the global biotechnology market.-Fineline Info & Tech
